Samuel Bates Martin - 17 Jun 2021 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP and CFO
Signature
/s/ Anthony S. Marucci, attorney in fact for Samuel Bates Martin
Issuer symbol
CLDX
Transactions as of
17 Jun 2021
Transactions value $
$0
Form type
4
Date filed
21 Jun 2021, 16:26
Next filing
12 Aug 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (right to buy) Award $0 +85K $0.00 85K 17 Jun 2021 Common Stock 85K $28.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
F2 25% vest on June 17, 2022 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.